This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Morphic Holding 将来の成長

Future 基準チェック /26

Morphic Holdingの収益は年間8.7%で減少すると予測されていますが、年間収益は年間76.5%で増加すると予測されています。EPS は年間減少すると予測されています。自己資本利益率は 3 年後に-71.2% 2.4%なると予測されています。

主要情報

-6.4%

収益成長率

-0.6%

EPS成長率

Biotechs 収益成長	28.4%
収益成長率	81.5%
将来の株主資本利益率	-87.8%
アナリストカバレッジ	Good
最終更新日	07 Aug 2024

今後の成長に関する最新情報

Recent updates

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Jun 26

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Jan 20

Companies Like Morphic Holding (NASDAQ:MORF) Are In A Position To Invest In Growth

Sep 29

We're Interested To See How Morphic Holding (NASDAQ:MORF) Uses Its Cash Hoard To Grow

Jun 07

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Feb 15

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Jan 03

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Nov 08

Morphic GAAP EPS of -$0.68 beats by $0.17, revenue of $60.2M

Aug 03

Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF)

May 06

Analyst Forecasts Just Became More Bearish On Morphic Holding, Inc. (NASDAQ:MORF)

Mar 01

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Feb 17

We're Not Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn

Nov 03

Morphic: Pioneering Integrin Medicines

Oct 13

業績と収益の成長予測

NasdaqGM:MORF - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1	-251	-203	-195	7
12/31/2025	1	-232	-191	-179	9
12/31/2024	0	-213	-173	-162	10
6/30/2024	N/A	-180	-138	-136	N/A
3/31/2024	N/A	-161	-129	-127	N/A
12/31/2023	1	-152	-114	-112	N/A
9/30/2023	7	-136	-110	-109	N/A
6/30/2023	9	-130	-106	-104	N/A
3/31/2023	69	-64	-105	-104	N/A
12/31/2022	71	-59	-101	-101	N/A
9/30/2022	74	-56	-97	-96	N/A
6/30/2022	75	-51	-97	-96	N/A
3/31/2022	19	-106	-92	-91	N/A
12/31/2021	20	-96	-84	-83	N/A
9/30/2021	16	-92	-78	-77	N/A
6/30/2021	39	-61	-49	-49	N/A
3/31/2021	43	-50	-48	-47	N/A
12/31/2020	45	-45	-47	-46	N/A
9/30/2020	39	-47	-47	-46	N/A
6/30/2020	19	-61	-65	-63	N/A
3/31/2020	17	-55	-63	-61	N/A
12/31/2019	17	-43	-44	-42	N/A
9/30/2019	21	-29	63	65	N/A
6/30/2019	15	-27	72	73	N/A
3/31/2019	9	-24	81	82	N/A
12/31/2018	3	-24	76	76	N/A

アナリストによる今後の成長予測

収入対貯蓄率: MORF今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MORF今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: MORF今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MORFの収益 ( 76.5% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: MORFの収益 ( 76.5% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: MORF 3 年以内に赤字になると予測されています。

This company has been acquired

Morphic Holding 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates decrease by 88%, EPS upgraded

Price target decreased by 10% to US$55.13

Consensus EPS estimates upgraded to US$3.41 loss

Price target decreased by 13% to US$65.38

Price target increased by 14% to US$73.88

Price target increased by 14% to US$73.88

Recent updates

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Morphic Holding, Inc., Annual General Meeting, Jun 04, 2024

Morphic Therapeutic Appoints Simon Cooper as Chief Medical Officer

Consensus revenue estimates decrease by 88%, EPS upgraded

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Key Executive exercised options and sold US$174k worth of stock

Insufficient new directors

Price target decreased by 10% to US$55.13

Consensus EPS estimates upgraded to US$3.41 loss

Morphic Holding, Inc. Announces Chief Executive Officer Changes

Third quarter 2023 earnings released: US$0.73 loss per share (vs US$0.78 loss in 3Q 2022)

Companies Like Morphic Holding (NASDAQ:MORF) Are In A Position To Invest In Growth

Price target decreased by 13% to US$65.38

Morphic Holdings Inc. Announces Chief Executive Officer, Praveen Tipirneni Suffered an Emergent Medical Event and Taking Medical Leave of Absence

CFO & COO notifies of intention to sell stock

Second quarter 2023 earnings released: US$0.92 loss per share (vs US$0.70 profit in 2Q 2022)

CEO, MD & Director exercised options and sold US$190k worth of stock

We're Interested To See How Morphic Holding (NASDAQ:MORF) Uses Its Cash Hoard To Grow

General Counsel & Secretary notifies of intention to sell stock

Price target increased by 14% to US$73.88

Price target increased by 14% to US$73.88

First quarter 2023 earnings: EPS and revenues miss analyst expectations

CFO & COO exercised options to buy US$279k worth of stock.

CFO & COO notifies of intention to sell stock

Consensus revenue estimates decrease by 29%, EPS upgraded

Full year 2022 earnings: EPS and revenues exceed analyst expectations

President exercised options and sold US$358k worth of stock

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Morphic Holding, Inc. announced that it expects to receive $29.999954 million in funding

CEO, MD & Director exercised options and sold US$123k worth of stock

We're Hopeful That Morphic Holding (NASDAQ:MORF) Will Use Its Cash Wisely

Morphic Therapeutic AnnouncesInitiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis

What Does The Future Hold For Morphic Holding, Inc. (NASDAQ:MORF)? These Analysts Have Been Cutting Their Estimates

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022

Morphic Therapeutic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022

Consensus revenue estimates increase by 437%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Morphic GAAP EPS of -$0.68 beats by $0.17, revenue of $60.2M

Price target decreased to US$66.43

Morphic Therapeutic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

Morphic Holding, Inc. Announces Management Appointments

Revenue Downgrade: Here's What Analysts Forecast For Morphic Holding, Inc. (NASDAQ:MORF)

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Morphic Holding, Inc., Annual General Meeting, Jun 08, 2022

Price target decreased to US$74.50

Morphic Therapeutic Announces Management Appointments

Chief Scientific Officer exercised options and sold US$367k worth of stock

Consensus revenue estimates fall by 38%

Analyst Forecasts Just Became More Bearish On Morphic Holding, Inc. (NASDAQ:MORF)

Price target decreased to US$75.80

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Morphic Holding, Inc. Announces Retirement of Dr. Nilesh Kumar from the Board and Resign as Member of the Board and the Audit and Nominating and Governance Committees

Here's Why We're Not Too Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn Situation

Price target decreased to US$83.80

General Counsel & Secretary exercised options to buy US$827k worth of stock.

Price target decreased to US$95.00

Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.17 profit in 3Q 2020)

CFO & COO exercised options and sold US$246k worth of stock

We're Not Worried About Morphic Holding's (NASDAQ:MORF) Cash Burn

CFO & COO exercised options and sold US$1.3m worth of stock

Morphic: Pioneering Integrin Medicines

Chief Scientific Officer notifies of intention to sell stock

Founder recently bought US$4.2m worth of stock